Richard E. Lowenthal - 02 Jan 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
PRESIDENT AND CEO, Director, 10%+ Owner
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Jan 2025, 16:30:37 UTC
Previous filing
19 Dec 2024
Next filing
22 Aug 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Award $0 +767,600 $0.000000 767,600 02 Jan 2025 Common Stock 767,600 $10.71 Direct F1
transaction SPRY Stock Option (right to buy) Award $0 +261,900 $0.000000 261,900 02 Jan 2025 Common Stock 261,900 $10.71 By Spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025.